Vaccines Against Tick-Borne Encephalitis Safe, Effective for Young Children: Presented at ESPID
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Vaccines Against Tick-Borne Encephalitis Safe, Effective for Young Children: Presented at ESPID

By Jenny Powers

NICE, France -- May 11, 2010 -- Children as young as 1 year can be protected from tick-borne encephalitis (TBE) with 2 vaccines that are also well tolerated, researchers reported here on May 7 at the 28th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID).

Eva Maria Pöllabauer, MD, Global Clinical and Medical Affairs Department, Baxter BioScience, Vienna, Austria, delivered results of an ongoing, single-blind, randomised, clinical study that investigated the immunogenicity and safety of 2 paediatric TBE vaccines (FSME-Immun Junior and Encepur).

The vaccine schedule included 2 doses of either FSME-Immun 0.25 mL or Encepur 0.25 mL followed by a third dose of FSME-Immun Junior only in children aged 1 to 11 years.

Twenty-eight days following the second vaccination, 100% of children in the FSME-Immun Junior group, were seropositive, compared with 94.0% and 96.7% respectively, in the Encepur group.

Local reactions occurred in 12.7% and 8.7% after the 1st and 2nd vaccination with FSME-Immun Junior and in 28.9% and 22.4% with Encepur. The rate of systemic reactions was comparable following the first and second immunisations, respectively with 9.3% and 4.7% occurring in the FSME-Immun Junior group and 11.8% and 5.3% in the Encepur group.

Less than 10% of the children in both groups had a mild fever. No serious adverse events were reported.

A general trend to higher antibody response was seen in the younger age groups.

[Presentation title: Immunogenicity and Safety of Two Tick-Borne Encephalitis Vaccines in Children. Abstract 558]


E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities